EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese subjects with Transthyretin Amyloid Cardiomyopathy - EPIC-ATTR

Study identifier:D8450C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Phase, Followed by An 80-week Open-label Extension Treatment Phase to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-Term Safety in Chinese Participants With Transthyretin Amyloid Cardiomyopathy (EPIC-ATTR)

Medical condition

Transthyretin Amyloid Cardiomyopathy

Phase

Phase 3

Healthy volunteers

No

Study drug

Eplontersen, Placebo

Sex

All

Estimated Enrollment

60

Study type

Interventional

Age

20 Years - 90 Years

Date

Study Start Date: 01 Dec 2023
Estimated Primary Completion Date: 15 Mar 2025
Estimated Study Completion Date: 16 Mar 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria